Trastuzumab deruxtecan in HER2+ gastric cancer overviewed by Arndt Vogel

Arndt Vogel, managing senior consultant and professor in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, shared a post on X:

“Trastuzumab deruxtecan in HER2+ gastric cancer

exploratory biomarker analysis of DESTINY Gastric01

64% concordance btw HER2+ IHC and blood
MET, EGFR and FGFR2 GA: ORR low
HER2 mutations: ORR high
activity in Her2 low.”

Read further.
Source: Arndt Vogel/X